|
SLC33A1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
6.08957329006898E-13 |
| Normal-vs-Stage3 |
1.62436730732907E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
4.251800E-01 |
| Stage1-vs-Stage3 |
7.755800E-03 |
| Stage1-vs-Stage4 |
3.409600E-04 |
| Stage2-vs-Stage3 |
1.151790E-02 |
| Stage2-vs-Stage4 |
1.998820E-03 |
| Stage3-vs-Stage4 |
2.116600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
4.159799948944E-09 |
| Normal-vs-Asian |
<1E-12 |
| Caucasian-vs-AfricanAmerican |
2.998400E-01 |
| Caucasian-vs-Asian |
8.038400E-01 |
| AfricanAmerican-vs-Asian |
2.698000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
5.544400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
2.05399999999578E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.846400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.336600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.354600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.843400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.627400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.009400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.36309999954065E-07 |
| Classical-VS-Follicular |
5.233800E-04 |
| Classical-VS-Other |
2.078400E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.43140055364199E-10 |
| Tall-VS-Other |
5.045800E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
4.408300E-02 |
| Follicular-VS-Normal |
1.25970345266069E-11 |
| Other-VS-Normal |
2.98859999969814E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.355060E-03 |
|
|
